The Supreme Court has clarified that offering stem cell therapy for autism spectrum disorder as a routine clinical service, outside an approved and monitored clinical trial, is unethical and amounts to medical malpractice. The ruling emphasizes that current scientific evidence does not establish stem cell therapy as a safe or effective treatment for autism, and therefore it does not meet the accepted standard of care. The Court noted that while stem cell research is an active and evolving field, its therapeutic use in autism remains experimental.
Authoritative guidelines from national regulatory and research bodies consistently state that there is insufficient and inconclusive evidence to support its clinical use for this indication. As a result, any practitioner who provides stem cell therapy for autism as a treatment service, rather than within a formally approved research protocol,…
